Skip to main content

Abstract 14106: The Efficacy of Sodium Glucose Co-transporter 2 Inhibitors in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Publication ,  Conference
Asad, ZUA; Jafry, A; Akhtar, K; Wang, A; Khan, MS; Khan, SU; Chung, MK; Piccini, JP; Stavrakis, S
Published in: Circulation
November 17, 2020

Atrial Fibrillation (AF) is common in patients with Type 2 diabetes mellitus and it is associated with adverse outcomes. The impact of SGLT-2 inhibitors on incident AF and cardiovascular outcomes is unknown. A systematic review of Medline, EMBASE and other online sources was conducted on 04/22/2020. All randomized controlled trials (RCTs) comparing SGLT-2 to placebo reporting incident AF were included. Mantel Haenszel random effects modeling was used to estimate risk ratios (RR) and I statistics were used to assess heterogeneity. A total of 33 RCTs (n=65,505 patients) were included. SGTL-2 inhibitor (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) use was not associated with statistically significant benefit in preventing AF [RR 0.91 (0.80-1.04)] (Figure-1). Subgroup analysis showed that only Dapagliflozin had a statistically significant effect in preventing AF [RR 0.79 (0.66-0.93), p=0.006, I =0%] (p<0.05 compared to others). SGLT-2 inhibitors were associated with a 25% relative risk reduction in the composite outcome of CV mortality or CV hospitalization in patients with history of AF [RR 0.75 (0.62-0.90)] and 27% in patients with no history of AF [RR 0.73 (0.66-0.81)]. SGLT-2 inhibitors prevent adverse cardiovascular outcomes regardless of baseline AF status. The protective effects of SGLT-2 inhibitors in preventing AF appear limited to Dapagliflozin.

Duke Scholars

Published In

Circulation

DOI

EISSN

1524-4539

ISSN

0009-7322

Publication Date

November 17, 2020

Volume

142

Issue

Suppl_3

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Asad, Z. U. A., Jafry, A., Akhtar, K., Wang, A., Khan, M. S., Khan, S. U., … Stavrakis, S. (2020). Abstract 14106: The Efficacy of Sodium Glucose Co-transporter 2 Inhibitors in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. In Circulation (Vol. 142). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1161/circ.142.suppl_3.14106
Asad, Zain Ul Abideen, Ali Jafry, Khawaja Akhtar, Allen Wang, Mohammad S. Khan, Safi U. Khan, Mina K. Chung, Jonathan P. Piccini, and Stavros Stavrakis. “Abstract 14106: The Efficacy of Sodium Glucose Co-transporter 2 Inhibitors in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” In Circulation, Vol. 142. Ovid Technologies (Wolters Kluwer Health), 2020. https://doi.org/10.1161/circ.142.suppl_3.14106.
Asad ZUA, Jafry A, Akhtar K, Wang A, Khan MS, Khan SU, et al. Abstract 14106: The Efficacy of Sodium Glucose Co-transporter 2 Inhibitors in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. In: Circulation. Ovid Technologies (Wolters Kluwer Health); 2020.
Asad, Zain Ul Abideen, et al. “Abstract 14106: The Efficacy of Sodium Glucose Co-transporter 2 Inhibitors in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Circulation, vol. 142, no. Suppl_3, Ovid Technologies (Wolters Kluwer Health), 2020. Crossref, doi:10.1161/circ.142.suppl_3.14106.
Asad ZUA, Jafry A, Akhtar K, Wang A, Khan MS, Khan SU, Chung MK, Piccini JP, Stavrakis S. Abstract 14106: The Efficacy of Sodium Glucose Co-transporter 2 Inhibitors in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Circulation. Ovid Technologies (Wolters Kluwer Health); 2020.

Published In

Circulation

DOI

EISSN

1524-4539

ISSN

0009-7322

Publication Date

November 17, 2020

Volume

142

Issue

Suppl_3

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology